ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 0312

The Use of Electromyography as a Screening Tool in Sarcoidosis-associated Neuropathy

Kristen Caldwell1, Sindhuja Koppu1, Huzaefah Syed2, Aamer Syed1, Jordana Kron1, Thomas Iden1 and Kelly Gwathmey1, 1Virginia Commonwealth University, Richmond, VA, 2Virginia Commonwealth University Medical Center, Richmond, VA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, neurology

Session Information

Date: Saturday, November 16, 2024

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Small fiber neuropathy (SFN) is the most common peripheral nervous system manifestation of sarcoidosis. Diagnosis of SFN includes clinical evaluation, occasionally skin biopsy to evaluate intraepidermal nerve fiber density, and electrodiagnostic studies. The utility of these tests to aid in diagnosis of sarcoidosis-associated SFN is unclear. This study evaluates the yield of normal electromyography (EMG) in diagnosing SFN.

Methods: This is a cross-sectional study comparing 19 patients with biopsy-confirmed sarcoidosis with and without normal EMG. Participants were evaluated for SFN according to the Toronto Consensus Criteria (TCC) with possible, probable, or definite SFN; the Utah Early Neuropathy Scale (UENS) that captures both small and large sensory fiber function; physician impression of neuropathy (PIN); and skin biopsy.

Results: In total, 19 patients with age ranging 30-70 years were recruited, including thirteen participants with normal EMG and 6 participants with abnormal EMG. Of this cohort, 66.7% of participants with abnormal EMG had PIN compared to 61.5% of those with normal EMG (p=1.00). Those with normal EMG had a lower mean UENS score (M=5.69, SD=4.50) compared to those with abnormal EMG (M=7.83, SD=5.49, p=0.43). When evaluated by TCC, 46.2% with normal EMG tested positive for SFN compared to 66.7% of those with abnormal EMG (p =0.63). In addition, 15.4% with normal EMG had positive biopsy suggesting pure SFN compared to 33.3% (p=0.59).

Conclusion: Though this study aimed to correlate normal EMG data with clinically suspected SFN, surprisingly 4 of 12 participants with clinically suspected SFN had abnormal EMG and 2 of 7 participants without suspected SFN had incidental EMG abnormalities. Notably, those with alternative causes of neuropathy (e.g., diabetes) were excluded. Participants with an abnormal EMG were more likely to have a higher UENS score, consistent with impaired large fiber function. Skin biopsy suggesting small fiber dysfunction was present in some patients with normal EMG (likely pure small fiber neuropathy) and some with abnormal EMG (likely mixed neuropathy). Although these findings were not statistically significant, there are clinically significant correlates. Despite a small sample size, our findings suggest that EMG studies may not be an adequate screening instrument for sarcoidosis-associated polyneuropathy.

Supporting image 1

Table 1. Biopsy-confirmed sarcoidosis patients, with normal and abnormal EMG, were evaluated for small fiber neuropathy utilizing various screening tools and histologic testing.

Supporting image 2

Figure 1. Mean total score of Utah Early Neuropathy Scale for participants with biopsy-confirmed sarcoidosis, comparing those with normal EMG and abnormal EMG.

Supporting image 3

Figure 2. Comparison of Participants with Abnormal and Normal Electromyogram. Graphs depict percentage of participants with abnormal skin biopsy suggestive of small fiber neuropathy, positive for small fiber neuropathy according to Toronto Consensus Criteria, and clinical impression of neuropathy by physician assessment.


Disclosures: K. Caldwell: None; S. Koppu: None; H. Syed: None; A. Syed: None; J. Kron: None; T. Iden: None; K. Gwathmey: None.

To cite this abstract in AMA style:

Caldwell K, Koppu S, Syed H, Syed A, Kron J, Iden T, Gwathmey K. The Use of Electromyography as a Screening Tool in Sarcoidosis-associated Neuropathy [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/the-use-of-electromyography-as-a-screening-tool-in-sarcoidosis-associated-neuropathy/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-use-of-electromyography-as-a-screening-tool-in-sarcoidosis-associated-neuropathy/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology